Characterization of opioid receptor-mediated regulation of incertohypothalamic dopamine neurons: lack of evidence for a role of 5-hydroxytryptaminergic neurons in mediating the stimulatory effects of morphine.
The purpose of the present study was to characterize opioid receptor-mediated regulation of incertohypothalamic dopaminergic (DA) neurons in the rat brain by examining the acute effects of selective mu or kappa opioid receptor agonists and antagonists on concentrations of 3,4-dihydroxyphenylacetic acid (DOPAC) in the medial zona incerta (MZI) and the dorsomedial hypothalamic nucleus (DMN) which contain cell bodies and terminals, respectively, of these neurons. Morphine caused a dose- and time-related increase in concentrations of DOPAC in MZI and DMN; this stimulatory effect was blocked by the mu opioid receptor antagonist naltrexone. In contrast, activation or blockade of kappa opioid receptors following administration of U-50,488 or nor-binaltorphimine, respectively, had no effect on DOPAC concentrations in either the MZI or DMN. The basal activity of incertohypothalamic DA neurons and their response to morphine was similar in male and female rats. Morphine also increased the concentrations of 5-hydroxyindoleacetic acid in MZI and DMN, indicating that morphine increases the activity of 5-hydroxytryptamine (5HT) neurons projecting to these regions. This might suggest that morphine-induced activation of incertohypothalamic DA neurons is mediated by 5HT neurons; but 5,7-dihydroxytryptamine-induced lesions of 5HT neurons did not alter the ability of morphine to increase DOPAC concentrations in MZI and DMN. These results indicate that the stimulatory effects of mu opioid receptor activation on incertohypothalamic DA neurons is not dependent upon the presence of 5HT neurons.
Tian
Y
Y
Department of Pharmacology and Toxicology, Michigan State University, East Lansing 48824.
Eaton
M J
MJ
Manzanares
J
J
Lookingland
K J
KJ
Moore
K E
KE
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D015115:5,6-Dihydroxytryptamine / Q000031:analogs & derivatives; D000818:Animals; D002404:Catheterization; D003404:Creatinine / Q000031:analogs & derivatives; D004298:Dopamine / Q000502:physiology*; D005260:Female; D007031:Hypothalamus / Q000187:drug effects / Q000502:physiology*; D007033:Hypothalamus, Middle / Q000187:drug effects / Q000502:physiology; D007276:Injections, Intraventricular; D008297:Male; D009020:Morphine / Q000494:pharmacology*; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D051381:Rats; D011957:Receptors, Opioid / Q000187:drug effects / Q000502:physiology*; D017473:Receptors, Opioid, kappa / Q000502:physiology; D017450:Receptors, Opioid, mu / Q000502:physiology; D012701:Serotonin / Q000502:physiology*
D011957:Receptors, Opioid; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu; D015102:3,4-Dihydroxyphenylacetic Acid; D012701:Serotonin; C078441:5,7-dihydroxytryptamine creatinine; D009020:Morphine; D003404:Creatinine; D004298:Dopamine; D015115:5,6-Dihydroxytryptamine